Biocon Ltd.

NSE: BIOCON BSE: 532523 SECTOR: Pharmaceuticals & Drugs  114k   709   176

282.85
-8.35 (-2.87%)
NSE: 07 Oct 03:59 PM

Price Summary

Today's High

₹ 290

Today's Low

₹ 281.8

52 Week High

₹ 410.7

52 Week Low

₹ 273.5

FinStar

Ownership Stable
Ownership strength is slightly missing the benchmark.
ValuationExpensive
The stock is at a premium valuation at this point.
EfficiencyPoor
The company seems highly inefficient in case of asset management.
FinancialsWeak
Watch out! The company might not be able to sustain any adverse condition.
*It is just an analytical rating of the company and not an investment advice.

Company Essentials

Market Cap

33958.97 Cr.

Enterprise Value

33345.57 Cr.

No. of Shares

120.06 Cr.

P/E

472.28

P/B

4.24

Face Value

₹ 5

Div. Yield

0.18 %

Book Value (TTM)

₹  66.75

CASH

689.3 Cr.

DEBT

75.9 Cr.

Promoter Holding

60.64 %

EPS (TTM)

₹  0.6

Sales Growth

-14.31%

ROE

1.09 %

ROCE

1.74%

Profit Growth

-69.3 %

* Total debt includes long term borrowing, short term borrowing plus current maturities of long-term borrowing
* Ratios are based on latest Audited Financial Result.

Your Added Ratios

Please login to Add & View your own added ratios.

Login

Brands

These are the brands of Biocon Ltd.

Insugen Basalog BIOMAb EGFR CANMAb ALZUMAb KRABEVA TACROGRAF

Index Presence

The company is present in 23 Indices.

Price Chart 1d 1w 1m 3m 6m 1Yr 3Yr 5Yr

 

Volume Chart 1d 1w 1m 3m 6m 1Yr 3Yr 5Yr

* Prices are based on daily market changes.
* The chart is based on the standalone earnings of the company. * Negative values and values more than 1000x in PE chart is considered 0.

Peer Comparison

View Full Peer Comparison
* The Peers list includes companies operating in the same industry and having comparable market cap.

 Group Companies

Track the companies of Group.

Ratios

Sales Growth

1 Year-14.31%
3 Year-15.62%
5 Year-7.65%

Profit Growth

1 Year-69.3%
3 Year-44.09%
5 Year-30.19%

ROE%

1 Year1.09%
3 Year3.61%
5 Year4.33%

ROCE %

1 Year1.74%
3 Year4.67%
5 Year5.29%

Debt/Equity

0.0095

Price to Cash Flow

713.42

Interest Cover Ratio

350.25

CFO/PAT (5 Yr. Avg.)

0.95580684993826

Share Holding Pattern

Promoter Pledging %

Date Promoter % Pledge %
Jun 2022 60.64 0
Mar 2022 60.64 0
Dec 2021 60.64 0
Sep 2021 60.64 0
Jun 2021 60.64 0
Investors List
* Figures given above are % of equity capital

 Strengths

  • Company is virtually debt free.
  • Company has a healthy Interest coverage ratio of 350.25.
  • The company has an efficient Cash Conversion Cycle of 69.204898901722 days.
  • Company has a healthy liquidity position with current ratio of 4.06532408190895.
  • The company has a high promoter holding of 60.64%.
  • The company has a strong degree of Operating leverage, Average Operating leverage stands at 3.08697232613484.

 Limitations

  • The company has shown a poor profit growth of -44.0920549392726% for the Past 3 years.
  • The company has shown a poor revenue growth of -15.6207955956801% for the Past 3 years.
  • Company has a poor ROE of 3.61486098904472% over the past 3 years.
  • Company has a poor ROCE of 4.67208678179024% over the past 3 years
  • The company is trading at a high PE of 472.28.
  • The company is trading at a high EV/EBITDA of 146.9734.

Quarterly Result (All Figures in Cr.)

PARTICULARS Jun 2021 Sep 2021 Dec 2021 Mar 2022 Jun 2022
Net Sales 382.7 364.8 473 517.7 441.7
Total Expenditure 359.2 388 438.7 491.2 439.1
Operating Profit 23.5 -23.2 34.3 26.5 2.6
Other Income 49.2 40.5 36.7 60.8 48.6
Interest 0.2 0.1 0.1 0 0.1
Depreciation 26 26.5 27.6 28.1 28.6
Exceptional Items 0 0 0 0 0
Profit Before Tax 46.5 -9.3 43.3 59.2 22.5
Tax 17.4 -2.7 17.8 21.1 7.6
Profit After Tax 29.1 -6.6 25.5 38.1 14.9
Adjusted EPS (Rs) 0.24 -0.06 0.21 0.32 0.12

Profit & Loss (All Figures in Cr. Adjusted EPS in Rs.)

PARTICULARS Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022
Net Sales 2419.2 2893.3 2184.2 2028.4 1738.2
Total Expenditure 2101 2554.3 1889.4 1717.2 1677.1
Operating Profit 318.2 339 294.8 311.2 61.1
Other Income 124.7 109.3 204.6 151.5 187.2
Interest 1 2.6 1.2 0.4 0.4
Depreciation 136.1 92.3 98 103.5 108.2
Exceptional Items 0 198.7 159.7 0 0
Profit Before Tax 305.8 552.1 559.9 358.8 139.7
Tax 67.3 59.4 119 78.3 53.6
Net Profit 238.5 492.7 440.9 280.5 86.1
Adjusted EPS (Rs.) 1.99 4.11 3.67 2.34 0.72

Balance Sheet (All Figures are in Crores.)

Particulars Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022
Equity and Liabilities
Share Capital 300 300 600 600 600.3
Total Reserves 6438.6 6815.4 6937.3 7307.1 7492.6
Borrowings 67.2 1.4 0.7 0 75.9
Other N/C liabilities -12.7 -71.6 -134.7 -30 -10.7
Current liabilities 831.6 993.3 728 550.2 590.9
Total Liabilities 7624.7 8038.5 8131.3 8427.3 8749
Assets
Net Block 858.8 1059.2 720.7 728.6 804.7
Capital WIP 318.5 254.5 151.9 164.6 270.3
Intangible WIP 0 0 0 14.6 14.6
Investments 3789 4021.6 4886.5 5142.9 5083.3
Loans & Advances 558.7 180.7 280.9 150.5 154.2
Other N/C Assets 42 11.1 7.6 56.8 19.7
Current Assets 2057.7 2511.4 2083.7 2169.3 2402.2
Total Assets 7624.7 8038.5 8131.3 8427.3 8749
* Other Non-current Liabilities include Net deferred Liabilities

Cash Flows (All Figures are in Crores.)

PARTICULARS Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022
Profit from operations 305.8 552.1 559.9 358.8 139.7
Adjustment 64.9 -111.8 -68.1 117.8 108.3
Changes in Assets & Liabilities 72.2 -193.9 -14 156 -172
Tax Paid -87.7 -136.9 -90.7 -61.3 -28.4
Operating Cash Flow 355.2 109.5 387.1 571.3 47.6
Investing Cash Flow -553.1 315.3 -188.9 -720.6 -302.1
Financing Cash Flow -54.6 -208.2 -128.9 27.8 112
Net Cash Flow -252.5 216.6 69.3 -121.5 -142.5

Corporate Actions

Investors Details

PARTICULARS Jun 2021% Sep 2021% Dec 2021% Mar 2022% Jun 2022%
Promoters 60.64 60.64 60.64 60.64 60.64
kiran mazumdar shaw 39.62 39.62 39.62 39.62 39.62
glentec internatio... 19.76 19.76 19.76 19.76 19.76
john mccallum mars... 0.70 0.70 0.70 0.70 0.70
ravi rasendra mazu... 0.40 0.40 0.40 0.40 0.40
yamini r mazumdar 0.11 0.11 0.11 0.11 0.11
dev mazumdar 0.04 0.04 0.04 0.04 0.04
PARTICULARS Jun 2021% Sep 2021% Dec 2021% Mar 2022% Jun 2022%
Investors 39.36 39.36 39.36 39.36 39.36
lici ulip-growth f... - - - 4.25 4.25
life insurance cor... - 4.24 4.24 - -
life insurance cor... 4.11 - - - -
ahan- i ltd 1.66 1.66 2.33 2.33 2.33
arohi emerging asi... - - 1.56 1.56 1.56
icici prudential f... - - - - -
arun suresh chanda... 1.10 1.10 1.10 1.10 1.10
aditya birla sun l... - - - - -
societe generale - - - - -
qualified institut... 0.61 - - - -
beneficial holding... 0.46 0.46 0.46 0.46 0.46
iepf 0.01 0.01 0.01 0.01 0.01

Annual Reports

Ratings & Research Reports

Company Presentations

Company News

Biocon informs about updates7 Oct 2022, 11:52AM EDQM conducts GMP inspection at Biocon’s Bangalore unit7 Oct 2022, 10:59AM Biocon informs about disclosure 14 Sep 2022, 12:36PM Biocon divests 5.4% stake in Syngene International7 Sep 2022, 10:11AM Biocon informs about analyst meet2 Sep 2022, 11:51AM Biocon informs about analyst meet19 Aug 2022, 12:08PM Biocon informs about updates17 Aug 2022, 12:35PM Biocon informs about press release5 Aug 2022, 1:09PM Biocon - Quaterly Results27 Jul 2022, 6:58PM Biocon - Quaterly Results27 Jul 2022, 6:58PM USFDA issues three observations to Biocon’s Telangana manufacturing plant 22 Jul 2022, 10:41AM Biocon informs about newspaper advertisement7 Jul 2022, 12:35PM Biocon’s arm gets EU GMP certification for new biologics manufacturing facility in Bengaluru6 Jul 2022, 9:20AM Biocon informs about AGM1 Jul 2022, 4:19PM Biocon to acquire 26% stake in AREREPL 30 Jun 2022, 9:09AM Biocon informs about analyst meet22 Jun 2022, 5:09PM Biocon informs about outcome of analyst meet14 Jun 2022, 9:52AM Biocon reports 19% fall in Q4 consolidated net profit29 Apr 2022, 11:19AM Biocon - Quaterly Results28 Apr 2022, 8:46PM Biocon - Quaterly Results28 Apr 2022, 8:46PM Biocon’s step down subsidiary bags contract from Malaysia to supply human insulin26 Apr 2022, 12:16PM Biocon informs about press release26 Apr 2022, 9:33AM Biocon informs about press release1 Apr 2022, 9:51AM Biocon informs about analyst meet31 Mar 2022, 10:27AM Biocon informs about investors meet24 Mar 2022, 4:05PM Biocon informs about investors meet23 Mar 2022, 3:52PM Biocon informs about credit rating11 Mar 2022, 4:44PM Biocon informs about analyst meet2 Mar 2022, 5:34PM Biocon informs about analyst meet2 Mar 2022, 9:23AM Biocon’s arm inks pact to acquire Viatris’ biosimilars business 28 Feb 2022, 9:17AM Biocon informs about acquisition28 Feb 2022, 9:13AM Biocon’s arm gets nod for Posaconazole Delayed-Release tablets from USFDA8 Feb 2022, 10:46AM Biocon informs about investor meet27 Jan 2022, 4:44PM Biocon informs about investor presentation21 Jan 2022, 12:37PM Biocon reports 18% rise in Q3 consolidated net profit 21 Jan 2022, 11:37AM Biocon informs about board meeting3 Jan 2022, 4:59PM Biocon informs about analyst meet17 Dec 2021, 4:56PM Biocon informs about institutional investor meet13 Dec 2021, 9:51AM Biocon informs about analyst meet10 Dec 2021, 12:46PM Biocon informs about press release7 Dec 2021, 9:49AM Biocon partners with Tabuk Pharmaceutical to commercialise speciality products in Middle East7 Dec 2021, 9:27AM Biocon’s arm gets USFDA nod for Mycophenolic Acid3 Dec 2021, 5:34PM Biocon selected in Dow Jones Sustainability Index for progressive ESG practices2 Dec 2021, 10:23AM Biocon informs about corrigendum 19 Nov 2021, 12:04PM Biocon informs about analsyt meet19 Nov 2021, 9:59AM Biocon informs about press release19 Nov 2021, 9:58AM Biocon informs about amended employees welfare trust deed18 Nov 2021, 4:32PM Biocon informs about investors meet17 Nov 2021, 12:42PM Biocon’s arm, Viatris launch Interchangeable Semglee Injection, Insulin Glargine Injection17 Nov 2021, 11:11AM Biocon informs about press release15 Nov 2021, 10:15AM

Biocon Stock Price Analysis and Quick Research Report. Is Biocon an attractive stock to invest in?

 

The Indian healthcare sector is expected to reach US$ 372 billion by 2022, driven by rising incomes, greater health awareness, lifestyle diseases and increasing access to insurance. Healthcare has become one of India’s largest sectors - both in terms of revenue and employment.

Healthcare comprises hospitals, medical devices, clinical trials, outsourcing, telemedicine, medical tourism, health insurance, and medical equipment. The structure of the healthcare delivery system in India consists of three broad segments: Primary care, Secondary care, and Tertiary care.

  • Primary care is the first point of contact between the population and the healthcare service providers. For example, Sub-center (SC), Primary Health Centre (PHC) and Community Health Centre (CHC) which is more relevant to rural areas (PHC’s).
  • Secondary care providers inpatient as well as outpatient medical services and includes simple surgical procedures. For example, District level & Mid-sized hospitals.
  • Tertiary care is the third level of the healthcare delivery system in the country. These hospitals are specialized consultative healthcare infrastructure. For example, Single specialty and Multi-specialty hospitals.

While healthcare services are offered by the public as well as private sectors, in urban as well as rural areas, generally people prefer private hospitals over public hospitals for treatment of diseases, illness, and sickness. So, let’s look into Biocon and its performance over the period of time.

  • Operating cash flow ratio: It measures the adequacy of a company’s cash generated from operating activities to pay off short-term financial obligations. Its cash from the operating activity was Rs 47.6 Cr.
     
  • Financial Strength: Health care organizations usually have high debt loads and low equity capital in their balance sheet. So, Debt to Equity ratio is important to analyze the company’s sustainability. Biocon has a Debt to Equity ratio of 0.0095 , which is a strong indication for the company.
     
  • EPS growth: Investors should ensure the EPS figure is growing faster than revenue numbers because it indicates company management is increasing the efficiency with which it runs the company. In Biocon , the EPS growth was -69.3219251336898 % which is bad for the company.
     
  • Operating profit margin: It determines a company's potential earnings. It assesses how well-managed a company with respect to its basic overhead costs and other operating expenses, Biocon has OPM of 3.51513059486826 % which is a bad sign for profitability.
     
  • ROE: Biocon have a poor ROE of 1.0896527285613 %. ROE is an important financial parameter for hospitals & health care companies because they expand and grow rapidly. Therefore, ROE measures how efficiently a shareholder's fund is used for generating profits.
Brief about Biocon

X